Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Current Liabilities (2017 - 2025)

Protagonist Therapeutics' Total Current Liabilities history spans 9 years, with the latest figure at $45.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 4.13% year-over-year to $45.4 million; the TTM value through Dec 2025 reached $45.4 million, down 4.13%, while the annual FY2025 figure was $45.4 million, 4.13% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $45.4 million at Protagonist Therapeutics, up from $44.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $47.4 million in Q4 2024 and bottomed at $21.3 million in Q4 2023.
  • The 5-year median for Total Current Liabilities is $39.5 million (2021), against an average of $37.3 million.
  • The largest annual shift saw Total Current Liabilities crashed 46.55% in 2023 before it soared 122.8% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $44.0 million in 2021, then fell by 29.16% to $31.2 million in 2022, then plummeted by 31.77% to $21.3 million in 2023, then skyrocketed by 122.8% to $47.4 million in 2024, then decreased by 4.13% to $45.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Total Current Liabilities are $45.4 million (Q4 2025), $44.9 million (Q3 2025), and $35.5 million (Q2 2025).